EUVIMEDEUVIMED entdecken
Crossref

CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma

Yushan Huang iD, Anqi Lin iD, Tianqi Gu iD, Shuang Hou iD, Jiarong Yao iD, Peng Luo iD, Jian Zhang iD

Immunotherapy · 2023

DOI: 10.2217/imt-2022-0175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Yushan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, Guangdong, China. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

There is an urgent need for appropriate biomarkers that can precisely and reliably predict immunotherapy efficacy, as immunotherapy responses can differ in skin cutaneous melanoma (SKCM) patients.

Methods

In this study, univariate regression models and survival analysis were used to examine the link between calcium voltage-gated channel subunit alpha 1C (CACNA1C) mutation status and immunotherapy outcome in SKCM patients receiving immunotherapy. Mutational landscape, immunogenicity, tumor microenvironment and pathway-enrichment analyses were also performed.

Results

The CACNA1C mutation group had a better prognosis, higher immunogenicity, lower endothelial cell infiltration, significant enrichment of antitumor immune response pathways and significant downregulation of protumor pathways.

Conclusion

CACNA1C mutation status is anticipated to be a biomarker for predicting melanoma immunotherapy effectiveness.

Aims

The treatment to make the immune system work better is also used to treat a skin cancer called skin cutaneous melanoma (SKCM). We need new ways to predict if the treatment will work.

Methods

We looked at two groups of people getting the treatment to make the immune system work better. One group had a special change in their bodies, and the other group did not. We looked at how this change affected the patients. We also looked at how to make their immune system stronger.

Results

We found that people with mutations tend to have better chances of getting better from their sickness.

Conclusion

We think that this might be a good way to tell if immunotherapy will work well for this type of SKCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansCalcium Channels, L-TypeImmune Checkpoint InhibitorsMutationPrognosisTumor MicroenvironmentCutaneous Malignant Melanoma

Stichwörter der Autor:innen

CACNA1Cbiomarkerimmune checkpoint inhibitormicroenvironmentskin cutaneous melanoma

Substanzen

CACNA1C protein, humanCalcium Channels, L-TypeImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, Guangdong, China.
  • The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Yushan Huang, Anqi Lin, Tianqi Gu, Shuang Hou, Jiarong Yao, Peng Luo, Jian Zhang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Huang, Y., Lin, A., Gu, T., Hou, S., Yao, J., Luo, P., & Zhang, J. (2023). CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma. Immunotherapy. https://doi.org/10.2217/imt-2022-0175

Vancouver

Huang Y, Lin A, Gu T, Hou S, Yao J, Luo P, et al. CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma. Immunotherapy. 2023. doi:10.2217/imt-2022-0175

BibTeX
@article{Huang2023,
  author = {Huang, Yushan and Lin, Anqi and Gu, Tianqi and Hou, Shuang and Yao, Jiarong and Luo, Peng and Zhang, Jian},
  title = {CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma},
  journal = {Immunotherapy},
  year = {2023},
  doi = {10.2217/imt-2022-0175}
}
Kostenlos starten →